Enveric Biosciences, Inc. (ENVB)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 15M 30M 45M Q4 '18: 43M Q1 '19: 42.6M Q2 '19: 42.6M Q3 '19: 41.1M Q4 '19: 39.9M Q1 '20: 38.8M Q2 '20: 36.1M Q3 '20: 35.4M Q4 '18 Q1 '19 Q2 '19 Q3 '19 Q4 '19 Q1 '20 Q2 '20 Q3 '20

Gross Profit TTM

0 3.5M 7M 10.5M Q4 '18: 9M Q1 '19: 8.8M Q2 '19: 8.8M Q3 '19: 8.3M Q4 '19: 8.2M Q1 '20: 7.9M Q2 '20: 7.3M Q3 '20: 7.3M Q4 '18 Q1 '19 Q2 '19 Q3 '19 Q4 '19 Q1 '20 Q2 '20 Q3 '20

Operating Income TTM

-10.5M -7M -3.5M 0 3.5M 7M 10.5M Q3 '24: -8.8M Q4 '24: -9.6M Q1 '25: -9.3M Q2 '25: -10M Q3 '25: -9.8M Q4 '25: -8.8M Q1 '26: -8.2M Q2 '26: -8.7M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income TTM

-10.5M -7M -3.5M 0 3.5M 7M 10.5M Q3 '24: -9.9M Q4 '24: -9.6M Q1 '25: -9.3M Q2 '25: -9.9M Q3 '25: -9.7M Q4 '25: -8.8M Q1 '26: -8.2M Q2 '26: -8.7M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue TTM

0 15M 30M 45M Q4 '18: 34M Q1 '19: 33.8M Q2 '19: 33.8M Q3 '19: 32.8M Q4 '19: 31.8M Q1 '20: 30.9M Q2 '20: 28.7M Q3 '20: 28.1M Q4 '18 Q1 '19 Q2 '19 Q3 '19 Q4 '19 Q1 '20 Q2 '20 Q3 '20

Operating Cash Flow TTM

-9M -6M -3M 0 3M 6M 9M Q3 '24: -8.2M Q4 '24: -7.7M Q1 '25: -7.5M Q2 '25: -6.5M Q3 '25: -7.7M Q4 '25: -8.1M Q1 '26: -8M Q2 '26: -8.6M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow TTM

-21M -14M -7M 0 7M 14M 21M Q4 '22: -17.7M Q1 '23: -17.8M Q2 '23: -17.6M Q3 '23: -15.8M Q4 '23: -14.1M Q4 '22 Q1 '23 Q2 '23 Q3 '23 Q4 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 1.5M 3M 4.5M Q1 '24: 266.8K Q2 '24: 505.9K Q3 '24: 48.4K Q1 '25: 149.8K Q2 '25: 216.3K Q3 '25: 313.2K Q1 '26: 1.5M Q2 '26: 4M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-180.00 -120.00 -60.00 0.00 60.00 120.00 180.00 Q3 '24: -170.70 Q4 '24: -113.84 Q1 '25: -119.21 Q2 '25: -127.14 Q3 '25: -94.85 Q4 '25: -37.54 Q1 '26: -24.04 Q2 '26: -13.15 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.